Bock, O <br/><br/>
Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.  [electronic resource] 

 -  Journal of musculoskeletal & neuronal interactions   
 - 144-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1108-7161 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Alendronate--administration & dosage<br/>Arthralgia--chemically induced<br/>Back Pain--chemically induced<br/>Bone Density Conservation Agents--administration & dosage<br/>Cohort Studies<br/>Drug Administration Schedule<br/>Etidronic Acid--administration & dosage<br/>Female<br/>Hemiterpenes--metabolism<br/>Humans<br/>Injections, Intravenous--adverse effects<br/>Lymphocyte Activation--drug effects<br/>Male<br/>Mevalonic Acid--metabolism<br/>Middle Aged<br/>Musculoskeletal Diseases--chemically induced<br/>Organophosphorus Compounds--metabolism<br/>Osteoporosis--drug therapy<br/>Pain--chemically induced<br/>Retrospective Studies<br/>Risedronic Acid<br/>T-Lymphocytes--drug effects